Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Gemifloxacin Mesylate

FDA-approved product (tablet, oral), marketed as Factive, Gemifloxacin Mesylate.

Registered studies
9
Lab records
17
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Gemifloxacin Mesylate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Bacterial disease

Indications ChEMBL records as approved, from FDA and DailyMed labels.

WHO therapeutic group
Fluoroquinolones
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC J01MA15

Repurposing investigation

Gemifloxacin Mesylate is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA>99% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • E. coli>99% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • K. pneumoniae92.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • M. tuberculosis88.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

9registered studies name this medicine, for any condition. See them below.

Experimental

  • MRSA: measured active in 4 of 4 lab records
  • E. coli: measured active in 8 of 8 lab records
  • K. pneumoniae: measured active in 5 of 5 lab records
Open Gemifloxacin Mesylate in ChEMBL Registered studies below
Show the 17 laboratory records, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.6 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.8 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.0 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.2 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Gemifloxacin Mesylate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • EFFECTS OF MOXIFLOXACIN AND GEMIFLOXACIN ON BLOOD GLUCOSE AND ECG MORPHOLOGY OF EUGLYCEMICS:A CLINICAL STUDY

    NCT04692623 · start 2021-03-01

    Registered record
    Registry ID
    NCT04692623
    Conditions
    Blood Glucose, Low; Hypoglycemia
    Interventions
    Moxifloxacin 400mg; Gemifloxacin 320 MG
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2021-03-01
    Completion
    2021-04-01
    Enrolment
    25

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBlood Glucose, Low; Hypoglycemia
    InterventionMoxifloxacin 400mg; Gemifloxacin 320 MG
    PhasePhase 1
    Registry statusCompleted

  • Oral Gemifloxacin Versus Intravenous Cefotaxime in Treatment of Spontaneous Bacterial Peritonitis

    NCT04168099 · start 2018-12-01

    Registered record
    Registry ID
    NCT04168099
    Conditions
    Spontaneous Bacterial Peritonitis
    Interventions
    Cefotaxime; Gemifloxacin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2018-12-01
    Completion
    2028-12-30
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSpontaneous Bacterial Peritonitis
    InterventionCefotaxime; Gemifloxacin
    PhasePhase 3
    Registry statusRecruiting

  • Fluoroquinolone Associated Disability

    NCT03535558 · start 2018-05-17

    Registered record
    Registry ID
    NCT03535558
    Conditions
    Bronchitis; Sinusitis; Urinary Tract Infections
    Interventions
    Fluoroquinolone (FQ); Azithromycin (AZ); Sulfamethoxazole/Trimethoprim (ST) Fixed Dose Combination
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2018-05-17
    Completion
    2018-12-31
    Enrolment
    239,306

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBronchitis; Sinusitis; Urinary Tract Infections
    InterventionFluoroquinolone (FQ); Azithromycin (AZ); Sulfamethoxazole/Trimethoprim (ST) Fixed Dose Combination
    PhaseNot recorded
    Registry statusCompleted

  • Comparison Between Rifampicin and Gemifloxacin and Ciprofloxacin in Treatment of Rhinoscleroma

    NCT03326050 · start 2018-02

    Registered record
    Registry ID
    NCT03326050
    Conditions
    Rhinoscleroma
    Interventions
    Gemifloxacin; Ciprofloxacin; Rifampicin
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Unknown
    Start
    2018-02
    Completion
    2018-10
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRhinoscleroma
    InterventionGemifloxacin; Ciprofloxacin; Rifampicin
    PhaseEarly phase 1
    Registry statusUnknown

  • A Study of Fluoroquinolones Exposure and Collagen-Related Serious Adverse Events

    NCT03479736 · start 2017-11-20

    Registered record
    Registry ID
    NCT03479736
    Conditions
    Retinal Detachment; Achilles Tendon; Aneurysm, Dissecting
    Interventions
    Oral Fluoroquinolones (FQ); Other Antibiotics; Febrile Illness Not Treated with Antibiotics Will be Analyzed as an Exposure
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2017-11-20
    Completion
    2018-06-04
    Enrolment
    117,911

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRetinal Detachment; Achilles Tendon; Aneurysm, Dissecting
    InterventionOral Fluoroquinolones (FQ); Other Antibiotics; Febrile Illness Not Treated with Antibiotics Will be Analyzed as an Exposure
    PhaseNot recorded
    Registry statusCompleted

  • Randomized Study on Efficacy of Gemifloxacin-based Regimen for Helicobacter Pylori Infection

    NCT02368470 · start 2015-02

    Registered record
    Registry ID
    NCT02368470
    Conditions
    Helicobacter Pylori Infection
    Interventions
    Gemifloxacin-based triple therapy; Standard triple therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2015-02
    Completion
    2015-10
    Enrolment
    252

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHelicobacter Pylori Infection
    InterventionGemifloxacin-based triple therapy; Standard triple therapy
    PhasePhase 3
    Registry statusUnknown

  • Efficacy of Combination Therapies for Gonorrhea Treatment

    NCT00926796 · start 2010-06

    Registered record
    Registry ID
    NCT00926796
    Conditions
    Gonorrhoea
    Interventions
    Azithromycin; Gentamicin; Gemifloxacin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2010-06
    Completion
    2013-05
    Enrolment
    614

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGonorrhoea
    InterventionAzithromycin; Gentamicin; Gemifloxacin
    PhasePhase 4
    Registry statusCompleted

  • Phase I Trial for Pharmacokinetic Characteristics of Factive 200mg Intravenous Formulation (Gemifloxacin 200mg) With Factive 320mg Tablet Formulation (Gemifloxacin 320mg)

    NCT01879007 · start 2006-01

    Registered record
    Registry ID
    NCT01879007
    Conditions
    Infectious Diseases
    Interventions
    Factive® Tab / Factive IV
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2006-01
    Completion
    Not recorded
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfectious Diseases
    InterventionFactive® Tab / Factive IV
    PhasePhase 1
    Registry statusCompleted

  • An Observational Study of Oral Fluoroquinolones and the Risk of Retinal Detachment

    NCT01881438 · start 2000-01

    Registered record
    Registry ID
    NCT01881438
    Conditions
    Retinal Detachment
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2000-01
    Completion
    2013-05
    Enrolment
    119,924

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRetinal Detachment
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted